Most biotech companies are concentrated in a handful of regions with deep ties to research universities, venture capital, and specialized talent. In the United States, the Boston-Cambridge corridor in Massachusetts and the San Francisco Bay Area dominate. Globally, the UK, Switzerland, China, and South Korea also host major clusters, but the US remains home to more biotech firms than any other country by a wide margin.
Boston-Cambridge: The World’s Densest Biotech Hub
Greater Boston, and specifically the Kendall Square area of Cambridge, is the single most concentrated biotech ecosystem on the planet. The region’s lab inventory has grown to 63.2 million square feet, with another 1.1 million square feet of lab and manufacturing space added in the most recent year alone. Nearly every major pharmaceutical company maintains a research presence here, drawn by proximity to Harvard, MIT, and a network of world-class teaching hospitals.
That said, the market is maturing. Massachusetts saw its first recorded decline in R&D jobs in 2024, losing about 1,100 positions (a 1.7% drop). This reflects a broader industry correction after years of aggressive pandemic-era hiring, not a signal that Boston is losing its grip. The cluster still ranks ninth globally across all innovation sectors when measured by scientific publications, patent filings, and venture capital activity.
San Francisco Bay Area
The San Jose-San Francisco corridor ranks third overall in the World Intellectual Property Organization’s global innovation cluster index, and it punches well above its weight in venture capital. The region captures 6.9% of all global VC deals, the highest share of any cluster in the world. South San Francisco in particular has branded itself “the birthplace of biotech,” a reference to Genentech’s founding there in 1976, and the city remains packed with biotech headquarters and lab campuses.
What distinguishes the Bay Area from Boston is its tighter overlap with the tech sector. Companies working in computational biology, AI-driven drug discovery, and genomic data platforms tend to cluster here, benefiting from the same software engineering talent pool that feeds Silicon Valley. The tradeoff is cost: office and lab rents are among the highest in the country, which pushes some startups toward cheaper alternatives.
Other Major US Clusters
Beyond the two dominant hubs, several US regions host significant biotech activity:
- San Diego has one of the largest biotech clusters on the West Coast, with particular strength in genomics and antibody therapeutics. The area around UC San Diego and the Torrey Pines mesa hosts hundreds of companies.
- New York City ranks seventh globally in overall innovation, driven largely by its 4.8% share of worldwide venture capital deals. Its biotech scene is smaller than Boston’s but growing, with new lab developments in Manhattan and the outer boroughs.
- Research Triangle, North Carolina is one of the fastest-growing biotech regions in the US. Major pharma companies including Merck, Novo Nordisk, Pfizer, Novartis, and Johnson & Johnson all operate across the state, and a lower cost of living compared to the coasts helps attract talent.
- Los Angeles cracks the global top 10 for innovation clusters, with a growing life sciences sector fed by UCLA, Caltech, and USC research programs.
- Virginia is an emerging player. Eli Lilly and AstraZeneca have both invested billions in the state recently, signaling growing interest in the Southeast as a manufacturing and research base.
Europe’s Biggest Biotech Centers
The United Kingdom leads Europe in biotech, with over 2,150 biopharma companies and the highest level of public research funding on the continent. The so-called “Golden Triangle” connecting London, Oxford, and Cambridge forms the core of the UK’s life sciences sector. London alone ranks eighth in the world for innovation activity, capturing 4.4% of global VC deals. The region benefits from a long history of publicly funded medical research and some of the world’s top-ranked universities.
Switzerland punches far above its population size. Basel, straddling the French and German borders, is home to Novartis and Roche and serves as the operational center for a dense network of smaller biotech firms. The Swiss system offers favorable regulatory conditions and proximity to a highly educated, multilingual workforce.
France and Germany round out the European picture, with Paris hosting notable cell therapy companies and Berlin-Munich emerging as a hub for digital health startups. The European biotech sector as a whole tends to be more dependent on public funding than its American counterpart, where private venture capital plays a larger role.
Asia-Pacific Clusters
China has rapidly built several biotech corridors. The Shanghai-Suzhou region ranks sixth globally for innovation, with 3.7% of global VC deals and 2.5% of scientific publications. Beijing ranks fourth, driven by massive government investment in genomics and cell therapy. The Shenzhen-Hong Kong-Guangzhou corridor tops the global innovation rankings overall, though its strength is broader than biotech alone, spanning electronics, AI, and advanced manufacturing.
South Korea’s Seoul cluster ranks fifth worldwide, fueled by strong patent activity (5.4% of global filings) and government-backed initiatives in biosimilars and precision medicine. Tokyo-Yokohama ranks second globally and leads the world in patent filings at 10.3% of the global share, though Japan’s biotech sector skews more toward established pharmaceutical companies than the startup-heavy model seen in the US.
What Drives Companies to These Locations
Biotech clusters form around a few predictable ingredients. The most important is proximity to research universities and academic medical centers, which supply both scientific discoveries and trained workers. A biotech startup typically begins when a university researcher licenses a discovery and raises venture funding to develop it. That process happens most easily when the lab, the lawyers, the investors, and the potential hires are all within a short drive of each other.
Venture capital access is the second major factor. The San Francisco Bay Area and Boston attract biotech founders in part because those cities have the deepest pools of investors who understand the long, expensive timelines of drug development. New York and London play similar roles as financial centers with growing life sciences investment arms.
The third driver is talent density. Biotech companies need a rare mix of PhD-level scientists, regulatory specialists, and manufacturing engineers. Regions that already have a critical mass of these workers make it easier to hire, which in turn attracts more companies, which trains more workers. This self-reinforcing cycle is why dominant clusters tend to stay dominant for decades, and why newer hubs like North Carolina and Virginia are investing heavily in workforce development to compete.
Cost is increasingly a factor pushing growth toward secondary markets. Lab space in Boston and San Francisco commands premium rents, and housing costs make it harder to recruit entry-level scientists. States like North Carolina and Virginia are capitalizing on this pressure by offering lower operating costs while still maintaining access to strong university systems and a growing base of experienced biotech professionals.